Your browser doesn't support javascript.
loading
Genetic Markers as Predictors for Response to Treatment and Possible Therapeutic Targets in Medulloblastoma.
Pérez-Pineda, Perla-Lidia; Ortiz-Butrón, Rocío; Pérez-De Marcos, Juan-Carlos; Hernández-Regino, Laura M; Zapata-Tarrés, Marta-Margarita; Torres-Espíndola, Luz-María.
Afiliação
  • Pérez-Pineda PL; Laboratory of Pharmacology, National Institute of Pediatrics, Mexico City, México.
  • Ortiz-Butrón R; Postgraduate Degree in Chemobiological Sciences, National School of Biological Sciences, National Polytechnic Institute, Mexico City, México.
  • Pérez-De Marcos JC; Department of Physiology, National School of Biological Sciences, National Polytechnic Institute, Mexico City, Mexico.
  • Hernández-Regino LM; Laboratory of Pharmacology, National Institute of Pediatrics, Mexico City, México.
  • Zapata-Tarrés MM; Postgraduate Degree in Chemobiological Sciences, National School of Biological Sciences, National Polytechnic Institute, Mexico City, México.
  • Torres-Espíndola LM; Laboratory of Pharmacology, National Institute of Pediatrics, Mexico City, México.
CNS Neurol Disord Drug Targets ; 22(5): 634-642, 2023.
Article em En | MEDLINE | ID: mdl-35579144
ABSTRACT

BACKGROUND:

Medulloblastomas (MB) are the most common malignant brain tumors in the pediatric age. In 2021, WHO categorized medulloblastomas into two groups molecularly defined and histologically defined medulloblastomas. Molecularly defined medulloblastomas are divided into WNTactivated medulloblastoma, SHH-activated and TP53-wildtype medulloblastoma, SHH-activated, and TP53-mutant and non-WNT/non-SHH medulloblastoma, which include Group 3 (MYC) and Group 4 (CDK6 and MYCN). In this paper, we will focus on molecularly defined medulloblastomas.

OBJECTIVE:

This paper aims to review the literature in order to describe the molecular structure of the medulloblastoma groups and to emphasize the importance of genetic predictors in medulloblastoma that can be used in clinical practice, either as a prognostic tool or as a therapeutic target in the future.

RESULTS:

Each molecular subtype of medulloblastoma presents a different prognosis, and the molecular subtype with the best prognosis is medulloblastoma-activated WNT. It has even been observed that a reduction in the intensity of the combined treatment does not modify the prognosis of the patients, resulting in even fewer adverse effects due to the treatment. On the other hand, it was observed that the subtypes with the worst prognosis are medulloblastomas with activated MYC and medulloblastomas with activated SHH and mutated TP53, due to their high capacity to metastasize or to their radio-resistance. However, a new target therapy has emerged that could help improve the prognosis in these patients.

CONCLUSION:

The deeper knowledge of the molecular pathways involved in the appearance and progression of medulloblastomas will allow us to offer a prognosis at the time of diagnosis and more specific treatments through the development of the targeted therapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Child / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Child / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article